Intranasal insulin treatment might boost cognition in people with mild cognitive impairment or Alzheimer's Disease, according to meta-analysis of 29 studies across multiple disorders
###
Article URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0286887
Article Title: Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
Author Countries: Canada
Funding: The authors received no specific funding for this work.
Journal
PLOS One
Article Title
Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
Article Publication Date
28-Jun-2023
COI Statement
The authors have read the journal’s policy and have the following competing interests: S.W. is supported by the Ontario Graduate Scholarship (OGS) and the Cleghorn Fellowship in Schizophrenia Studies outside of the submitted work. N.S. is supported by the Ontario Graduate Scholarship (OGS) and Banting and Best Diabetes Centre (BBDC) Novo-Nordisk Graduate Studentship outside of the submitted work. M.H. is supported in part by an Academic Scholars Award from the Department of Psychiatry, University of Toronto, and has grant support from the Banting and Best Diabetes Centre (BBDC), the Canadian Institutes of Health Research (CIHR), PSI Foundation, Ontario, holds the Kelly and Michael Meighen Chair in Psychosis Prevention, and the Cardy Schizophrenia Research Chair outside of the submitted work. She is also supported by the Danish Diabetes Academy, and a Steno Diabetes Centre Fellowship Award outside of the submitted work. T.K.R. has received research support from Brain Canada, Brain and Behavior Research Foundation, Bright Focus Foundation, Canada Foundation for Innovation, Canada Research Chair, Canadian Institutes of Health Research, Centre for Aging and Brain Health Innovation, National Institutes of Health, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, and the Weston Brain Institute outside of the submitted work. G.R. has received research support from the Canadian Institutes of Health Research (CIHR), University of Toronto, Research Hospital Fund–Canada Foundation for Innovation (RHF-CFI), and HLS Therapeutics Inc. outside of the submitted work. S.M.A. is supported in part by an Academic Scholars Award from the Department of Psychiatry, University of Toronto, and has grant support from CIHR, PSI Foundation, Ontario, and the CAMH Discovery Fund outside of the submitted work. M.H. receives consultant fees from Alkermes Inc. G.R. has received advisory board support from HLS Therapeutics and consultant fees from Mitsubishi Tanabe Pharma Corporation outside of the submitted work. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.